ELCC: Post Hoc Analyses Confirm Benefit of First-Line Pembrolizumab in NSCLC
Recorded Courses
hosted byProjects In Knowledge Inc. (PIK)
hosted byProjects In Knowledge Inc. (PIK)
attend it anywhere online
category
Medicine
Oncology
price
Free
ELCC: Post Hoc Analyses Confirm Benefit of First-Line Pembrolizumab in NSCLC is organized by Projects In Knowledge Inc. (PIK).
Release Date: Apr 07, 2023
Termination Date: Apr 06, 2024
Learning Objective(s):
• Summarize recent clinical trial findings utilizing immunotherapy for patients with treatment naïve advanced or metastatic NSCLC.
• Discuss long-term outcomes of immunotherapy treatment in NSCLC.
Additional details will be posted as soon as information is available.